PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
22.78%
Cost of revenue up >15% signals severe cost pressure. Seth Klarman would demand evidence of corresponding revenue growth.
-30.37%
Negative gross profit growth is a serious warning sign. Benjamin Graham would demand thorough analysis of pricing power and cost structure.
-30.37%
Negative gross margin growth suggests serious pricing or cost issues. Benjamin Graham would demand thorough analysis.
45.24%
R&D growth above 10% signals aggressive investment. Seth Klarman would demand evidence of future payoff potential.
-4.95%
Negative G&A growth (overhead reduction) needs verification. Benjamin Graham would examine impact on operations.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
24.69%
Operating expenses growth above 10% signals concerning cost expansion. Seth Klarman would demand justification.
24.69%
Total costs growth above 5% signals concerning expansion. Seth Klarman would demand justification.
No Data
No Data available this quarter, please select a different quarter.
22.78%
D&A growth above 10% signals heavy asset expansion. Seth Klarman would demand evidence of future payoff.
-24.88%
Negative EBITDA growth needs thorough analysis. Benjamin Graham would examine operational issues.
-24.88%
Negative EBITDA margin growth needs thorough analysis. Benjamin Graham would examine operational issues.
-24.83%
Negative operating income growth needs thorough analysis. Benjamin Graham would examine operational issues.
-24.83%
Negative operating margin growth needs thorough analysis. Benjamin Graham would examine operational issues.
291.57%
Other expenses growth above 30% signals concerning expansion. Seth Klarman would scrutinize unusual items.
-21.98%
Negative pre-tax income growth needs thorough analysis. Benjamin Graham would examine operational issues.
-21.98%
Negative pre-tax margin growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-17.79%
Negative net income growth needs thorough analysis. Benjamin Graham would examine operational issues.
-17.79%
Negative net margin growth needs thorough analysis. Benjamin Graham would examine operational issues.
-12.12%
Negative EPS growth needs thorough analysis. Benjamin Graham would examine operational issues.
-9.09%
Negative diluted EPS growth needs thorough analysis. Benjamin Graham would examine operational issues.
5.06%
Share increase above 2% signals significant dilution. Seth Klarman would demand explanation.
6.04%
Diluted share increase above 2% signals significant dilution. Seth Klarman would demand explanation.